Basic & Clinical Pharmacology & Toxicology

Volume 130, Issue 4 pp. 553-556

SHORT COMMUNICATION

Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database

Satoru Mitsuboshi,

Corresponding Author

Satoru Mitsuboshi

[email protected]

orcid.org/0000-0002-6244-1253

Department of Pharmacy, Kaetsu Hospital, Niigata, Japan

Correspondence

Satoru Mitsuboshi, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata 956-0814, Japan. Email: [email protected].

Search for more papers by this author

Takahiro Niimura,

Takahiro Niimura

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Search for more papers by this author

Fuka Aizawa,

Fuka Aizawa

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Mitsuhiro Goda,

Mitsuhiro Goda

Clinical Research Centre for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Yoshito Zamami,

Yoshito Zamami

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Keisuke Ishizawa,

Keisuke Ishizawa

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Satoru Mitsuboshi,

Corresponding Author

Satoru Mitsuboshi

[email protected]

orcid.org/0000-0002-6244-1253

Department of Pharmacy, Kaetsu Hospital, Niigata, Japan

Correspondence

Satoru Mitsuboshi, 1459-1 Higashikanazawa, Akiha-ku, Niigata-shi, Niigata 956-0814, Japan. Email: [email protected].

Search for more papers by this author

Takahiro Niimura,

Takahiro Niimura

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Search for more papers by this author

Fuka Aizawa,

Fuka Aizawa

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Mitsuhiro Goda,

Mitsuhiro Goda

Clinical Research Centre for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Yoshito Zamami,

Yoshito Zamami

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

Keisuke Ishizawa,

Keisuke Ishizawa

Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan

Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan

Search for more papers by this author

First published: 16 February 2022

https://doi.org/10.1111/bcpt.13717

Satoru Mitsuboshi and Takahiro Niimura contributed equally to this work.

Funding information: Japan Society for the Promotion of Science, Grant/Award Number: 20H05798; Japan Society for the Promotion of Science Grant-in-Aid for Transformative Research Areas (B)

Share a link

Email
Wechat
Bluesky

CONFLICT OF INTEREST

The authors have no competing interests to declare.

Open Research

DATA AVAILABILITY STATEMENT

Data supporting the findings of this study are available from the author upon reasonable request.

REFERENCES

1Zhou H, Sim JJ, Shi J, Shaw SF, Lee MS, Neyer JR, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ β-blocker use and risk of mortality in heart failure patients initiating maintenance dialysis. Am J Kidney Dis 2021; 77(5): 704-712. doi:10.1053/j.ajkd.2020.07.023
10.1053/j.ajkd.2020.07.023
CAS PubMed Web of Science® Google Scholar
2Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail 2019; 7(5): 371–382. doi:10.1016/J.JCHF.2019.02.009
10.1016/J.JCHF.2019.02.009
PubMed Web of Science® Google Scholar
3Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 1979; 25(4): 408–415. doi:10.1002/cpt1979254408
10.1002/cpt1979254408
CAS PubMed Web of Science® Google Scholar
4Hoot NR, Benitez JG, Palm KH. Hemodynamically unstable: Accidental atenolol toxicity? J Emerg Med 2013; 45(3): 355–357. doi:10.1016/j.jemermed.2013.03.027
10.1016/j.jemermed.2013.03.027
PubMed Web of Science® Google Scholar
5D'Angelo K, Paul S, Ranjeeta F, Fogel J, Chikvashvili D, Rubinstein S. Awareness and knowledge among internal medicine house-staff for dose adjustment of cardiovascular drugs in chronic kidney disease. High Blood Press Cardiovasc Prev 2021; 28(2): 177–184. doi:10.1007/s40292-021-00438-w
10.1007/s40292?021?00438?w
PubMed Web of Science® Google Scholar
6Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18(6): 427–436. doi:10.1002/PDS.1742
10.1002/PDS.1742
CAS PubMed Web of Science® Google Scholar
7Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol 2018; 14(3): 151–164. doi:10.1038/nrneph.2017.181
10.1038/nrneph.2017.181
PubMed Web of Science® Google Scholar
8Fleet JL, Weir MA, McArthur E, et al. Kidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults. Am J Kidney Dis 2014; 64(6): 883–891. doi:10.1053/j.ajkd.2014.06.009
10.1053/j.ajkd.2014.06.009
CAS PubMed Web of Science® Google Scholar
9Santos J, Oliveira P, Severo M, Lobato L, Cabrita A, Fonseca I. Different kidney function trajectory patterns before dialysis in elderly patients: clinical implications and outcomes. Ren Fail 2021; 43(1): 1049–1059. doi:10.1080/0886022X.2021.1945464
10.1080/0886022X.2021.1945464
PubMed Web of Science® Google Scholar
10Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 2016; 18(7): 744–758. doi:10.1002/ejhf.600
10.1002/ejhf.600
PubMed Web of Science® Google Scholar

Volume130, Issue4

April 2022

Pages 553-556

Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Related

Information